Millions of community health center patients could lose access to care if Congress and the Biden administration fail to extend telehealth flexibilities granted during the COVID-19 pandemic, especially for audio-only telehealth, a new survey report warns.
Sixteen states have passed laws since 2019 addressing pharmacy benefit manager (PBM) discrimination against 340B covered entities, according to a draft summary of state action on the subject circulating among community health center advocates.
Meanwhile, two longtime 340B program policy
…
A recent U.S. Supreme Court decision is spurring more states to enact laws banning pharmacy benefit managers (PBMs) from reimbursing 340B pharmacies less for prescription drugs than non-340B providers, health care lawyers say in a new paper.
Prescription drug sales through the 340B program totaled $38 billion in calendar year 2020, representing 7.2% of overall U.S. sales of $528 billion, Drug Channels blog reports. Drug Channels is run by pharmaceutical manufacturer consultant Adam Fein, a leading critic
…
Congressional Medicare policy advisers today recommended Medicare Part B drug reimbursement changes that hospitals say would amplify the effect of Part B drug payment cuts for 340B hospitals in place since 2018. …
Please Login or Become
Federally qualified health centers in some rural communities have stepped up and maintained access to health care following rural hospital closures, advisers to Congress on Medicare reported today. …
Please Login or Become a Paid Subscriber to
As we described in Parts 2 and 3 of this series, in 2018, an ex-Celgene vice president responsible for the company’s 340B program compliance alleged in a whistleblower lawsuit that Celgene’s reason for limiting Revlimid, Pomalyst, and Thalomid’s distribution is …
Last September, the Democratic-controlled U.S. House Oversight and Reform Committee released a 45-page report focused on Celgene and Bristol Myers Squibb’s (BMS’s) nearly two dozen price increases on Revlimid from 2005, when Celgene bought the drug, through 2019. It was …
The impact on health care providers of being unable to access Revlimid at the 340B price is significant, financially and in terms of patient care, according to numerous health system representatives that 340B Report interviewed. (All current and former health …
The myeloma drugs Revlimid and Pomalyst are analogues of Thalomid, aka thalidomide—a drug that still haunts those who remember the late 1950s and early 1960s. Marketed mainly in Europe as an over the counter sedative and morning sickness medicine for …